Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Ocugen Inc OCGN

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:OCGN)

ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN

PR Newswire 4 hours ago

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

Accesswire 9 hours ago

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

Newsfile 10 hours ago

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN

Accesswire 11 hours ago

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

GlobeNewswire 14 hours ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

GlobeNewswire 16 hours ago

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen

Newsfile 20 hours ago

Lifshitz Law PLLC Announces Investigations of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), bluebird bio, inc. (NASDAQ: BLUE), Sonder Holdings, Inc. (NASDAQ: SOND), and Ocugen Inc. (NASDAQ: OCGN)

Accesswire 1 day ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN

Newsfile 1 day ago

Opinion & Analysis (NDAQ:OCGN)

No current opinion is available.

Bullboard Posts (NDAQ:OCGN)

Ocugen to Present on Modifier Gene Therapy Platform at Assoc

Just In: $OCGN Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual...
whytestocks - 8 hours ago

Ocugen to Participate in Fireside Chat at the Emerging Growt

News; $OCGN Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble...
whytestocks - April 12, 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with St

Breaking News: $OCGN Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial...
whytestocks - February 22, 2024

Kevin Harrington Discusses FSD Pharma

<< View Post To Watch Video >> I believe this new product will aid society in reducing the number of alcohol-related...
Richardson35 - April 13, 2023

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent

   
Richardson35 - July 15, 2022

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

<< View Post To Watch Video >>
Richardson35 - June 3, 2022